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Most individuals exposedtohepatitisCvirus (HCV)becomechronically infectedandarepredisposed
to liver disease. The mechanisms underlying viral persistence and disease progression are unknown. A
role for the HCV NS5A protein in viral replication and interferon resistance has been demonstrated.
To identify mechanisms affected by NS5A, we analyzed the gene expression of Huh7 cells expressing
NS5A and control cells using oligonucleotide microarrays. A set of 103 genes (43 up-regulated, 60
down-regulated)whoseexpressionwasmodifiedbyat least twofoldwasselected.These includedgenes
involved in cell adhesion and motility, calcium homeostasis, lipid transport and metabolism, and
genes regulating immune responses. The finding of modulated expression of genes related to the
TGF- superfamily and liver fibrosis was observed. Interestingly, both the tumor necrosis factor and
lymphotoxin beta receptors were down-regulated by NS5A. Similar data were obtained following
expression of four NS5A mutants obtained from patients who were not responsive or were sensitive to
interferon therapy. Through computational analysis, we determined that 39 of the 43 genes up-
regulated by NS5A contained one or more nuclear factor B (NF-B) binding sites within their
promoter region. Using the Gibbs sampling method, we also detected enrichment of NF-B consen-
sus binding sites in the upstream regions of the 43 coexpressed genes. Activation of NF-B by NS5A
was subsequently demonstrated in luciferase reporter assays. Adenovirus-mediated expression of
IB reverted NS5A mediated up-regulation of gene expression. In conclusion, this study suggests a
role of NS5A and NF-B in HCV pathogenesis and related liver disease. Supplementary material for
this article can be found on the HEPATOLOGY website (http://interscience.wiley.com/jpages/0270-9139/
suppmat/index.html). (HEPATOLOGY 2004;40:708–718.)
Hepatitis C virus (HCV) is a highly prevalentpathogen associated with a high subsequent riskof progression to liver cirrhosis and hepatocel-
lular carcinoma (HCC).1 The HCV genome is a positive-
stranded RNA of 9.6 kb that encodes for a polyprotein
precursor, which is co- and posttranslationally processed
to yield 10 structural and nonstructural proteins (C, E1,
E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B).2
Several studies have suggested a role of NS5A in resis-
tance to interferon (IFN)- treatment.3–7 We and others
reported an altered cellular response to IFN- and a con-
comitant up-regulation of interleukin (IL)-8 by NS5A.8,9
It has also been reported that NS5A participates in HCV
viral replication10–14 and is a potent transcriptional acti-
vator.15 Therefore, identification of cellular genes modi-
fied by NS5A in hepatocytic cells may provide insight into
the role of NS5A in HCV replication and pathogenesis.
We used microarrays to compare the gene expression pro-
file between control Huh7 cells and Huh7 cells expressing
a NS5A mutant isolated from a patient infected with
HCV-1b and resistant to IFN- therapy. We subse-
quently compared the effects of four NS5A mutants iso-
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lated from patients who were responsive or nonresponsive
to IFN- therapy upon transient expression in Huh7
cells.
The computational identification of transcription fac-
tor binding sites through the analysis of DNA sequence
data has recently emerged as a major technology for the
elucidation of transcription regulatory networks. We used
computer-based approaches such as the Gibbs sampling
method to determine common transcription factor motifs
in the promoters of the genes up-regulated by NS5A.
Patients and Methods
Cell Culture and Transient NS5A Expression.
NS5A sequences were isolated from 4 patients infected
with HCV 1b, treated with standard IFN- therapy (3 to
6 MU, 3 times per week for 6 months). Three NS5A
sequences from 1 responder (R1) and 2 nonresponder
(NR1 and NR2) patients to IFN- treatment were previ-
ously described.7 The fourth NS5A sequence, isolated
from a responder (R2) patient, was amplified, sequenced,
and cloned in the pCDNA3.1 vector (Invitrogen, Carls-
bad, CA) using the same methodology.7 We established
Huh7 clones expressing the R1, NR1, and NR2 NS5A
mutants.7 Herein, we used the control clones T1 and T2
and two clones, F1 and F11, expressing the NS5A mutant
NR1.7 For transient NS5A expression, Huh7 cells were
transfected via addition of 30 L of lipofectamine
(GIBCO BRL, Gaithersburg, MD) and 15 g of the plas-
mid containing NR1, NR2, R1, and R2 NS5A sequences
or the empty vector in OPTIMEM I medium (GIBCO
BRL). In additional experiments, Huh7 cells were co-
transfected with 4 g of the pEGFP vector encoding the
green fluorescence protein (GFP) (Clontech, La Pont de
Claix, France) as a monitor for transfection efficiency.
The efficiency of transfection was approximately 50%–
60%.
SDS–Polyacrylamide Gel Electrophoresis and
Western Blot Analysis. Total proteins (50 g) were di-
luted in Laemmli sample buffer, resolved via 10% SDS–
polyacrylamide gel electrophoresis (SDS-PAGE), and
transferred onto nitrocellulose membranes (Schleicher
and Schuell, Dasel, Germany). The membranes were in-
cubated with monoclonal antibodies against NS5A (Bio-
genesis Ltd., Poole, United Kingdom) (1:1,000 dilution)
and actin (ICN, Costa Mesa, CA) (1:20,000 dilution) or
with polyclonal antibodies against lymphotoxin beta re-
ceptor (LTBR) (R&D systems, Minneapolis, MN) (1:
5,000 dilution) and IB (Santa Cruz Biotechnology,
Santa Cruz, CA) (1:1,000 dilution). Immunodetection
was realized using enhanced chemiluminescence reagents
(Amersham, Buckinghamshire, United Kingdom).
Adenovirus Infection. F1 and F11 cells were plated at
a density of 4  105 per well in 6-well tissue culture plates.
Twenty-four hours later, the cells were infected with the
adenoviruses AdIB and AdGFP, with a cytomegalovi-
rus (CMV) promoter driving expression of full-length
IB complementary DNA (cDNA) and GFP, respec-
tively. Fluorescence microscopy confirmed that adenovi-
rus-transferred genes were expressed in nearly 100% of
cells 18 hours after infection.
Luciferase Reporter Assays. Luciferase assays were
performed using an E-selectin luciferase plasmid and re-
agents from Promega (Madison, WI) in the single and
dual format by monitoring the transfection efficiency
with pRL-TK.
Preparation of Complementary RNA and Gene
Chip Hybridization. Total RNA was isolated and used
to generate complementary RNA probes. Preparation of
complementary RNA, hybridization, and scanning of the
HuGeneFL Arrays (Affymetrix, Inc., Santa Clara, CA)
were performed as described previously.8 Data analysis
was performed using GeneChip 4.0 software (Affymetrix,
Inc.). Genes differently modified by NS5A were com-
pared in F1 and F11 clones with each control cell line (T1
and T2) and then selected (fold change 2, P  .05). For
each gene, the fold change between NR1 and control
clones was calculated for 2 experiments using Affymetrix
software (Affymetrix, Inc.).
Reverse Transcription Followed by Polymerase
Chain Reaction. Single-stranded cDNA was synthe-
sized from total RNA using Superscript II reverse tran-
scriptase (GIBCO-BRL) and random hexamers
(GIBCO-BRL) as primers. For regular reverse-tran-
scriptase polymerase chain reaction (RT-PCR), the re-
action mixture was composed of 1 L of cDNA
template obtained from 1 g extracted RNA; 25 pmol
primers; 25 nmol each deoxyribonucleoside triphos-
phate; 2.5 U Taq DNA polymerase (GIBCO-BRL);
and 5 L 10 polymerase chain reaction (PCR) buffer
in a final volume of 50 L. The nucleotide sequences of
primers and corresponding annealing temperatures
used are as indicated (Table 1). Primers for real-time
PCR were designed using the PRIMER3 program
(http://www.genome.wi.mit.edu) (see Table 1). As an
internal reference, actin was amplified in parallel with
the genes of interest. All reactions were carried in 20
L volumes containing 10 L of iQ SYBR Green Su-
permix (Bio-Rad, Hercules, CA), 1 L (25 pmol) of
each primer and 5 L of cDNA product. Reactions
were performed in the Bio-Rad iCycler iQ Optical de-
tection system. Meltcurves were also performed to de-
termine unique amplification products.
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Quantitative Enzyme-Linked Immunosorbent As-
say for TGF-1. The amount of TGF-1 present in the
culture media of the T1, T2, F1, and F11 clones were
measured with Quantikine TGF-1 enzyme-linked im-
munosorbent assay (R&D Systems). The supernatants
were activated with 1 N HCl for 10 minutes and neutral-
ized with 1.2 N NaOH and 0.5 M hydroxyethylpipera-
zine-N-2 ethanesulfonic acid. The captured TGF-1
proteins were quantitated at 450 nm in a spectrophotom-
eter. Two independent experiments as well as two inde-
pendent measures were performed for each sample.
Computational Promoter Analysis. Human genomic
sequences were obtained from http://genome.ucsc.edu.
Corresponding human messenger RNA (mRNA) se-
quences encoding for the N terminus of each protein were
obtained from the National Center for Biotechnology
Information GenBank RefSeq database (available at
http://www.ncbi.nlm.nih.gov/Genbank/index.html) and
subsequently aligned with the genomic sequence to iden-
tify the transcription start site. Promoter regions were
then defined from this transcription start site—1 kbp up-
stream and 1 kbp downstream—and analyzed using
MATCH, a weight matrix–based tool for searching pu-
tative transcription factor biding sites in DNA sequenc-
es.16,17 MATCH assigns matrix and core similarity values
for each transcription factor based on the position weight
matrices. The cutoff values for core and matrix similarities
used were 0.85. Promoter region comparison was per-
formed by entering the defined promoter sequences into
the Gibbs Motif Sampler (http://bayesweb.wadsworth.
org/gibbs/gibbs.html). The Gibbs Motif Sampler is a soft-
ware for locating multiple transcription factor binding
sites for multiple transcription factors simultaneously in
unaligned DNA sequences.18 Motif searches were speci-
fied between 14–25 bp in length. Sequences with score
values of 1.000 for core and 0.500 for matrix were se-
lected. The internal Wilcoxon signed rank test was also
used in the assessment of statistical significance of our
data sets. Pictograms of the Gibbs output were generated
using software available at http://genes.mit.edu/pictogram.
html to show the relative frequency of each base within
the returned motifs.
Results and Discussion
Gene Expression Profile of Huh7 Cells Expressing
NS5A. Hepatocytic Huh7 cells expressing NS5A mu-
tants isolated from patients infected with HCV-1b were
generated as described previously.7 We wished to com-
pare the gene expression profile of clones F1 and F11
expressing the NS5A NR1 mutant isolated from a nonre-
sponder to IFN- therapy with control clones T1 and T2
expressing the empty vector using oligonucleotide arrays
complementary to 6,800 genes. Expression levels of
NS5A in these cells are shown in Fig. 1. Two independent
experiments were performed. RNA transcript levels from
both NS5A expressing cell lines F1 and F11 were com-
pared with control cell lines T1 and T2. We selected genes
that differed in their expression levels by twofold or
greater in each comparison pair and in both experiments,
with a P value of less than .05. The 103 genes that were
identified are presented in Tables 2 and 3 for up-regulated
and down-regulated genes, respectively. Changes in-
cluded differential expression of genes related to cell ad-
hesion and motility. Expression of trefoil factors 1 and 2,








Actin 5-ATCATGTTTGAGACCTTCAA-3 644 60
5-TTGCGCTCAGGAGGAGCAAT-3
Actin 5-TGGACTTCGAGCAAGAGATGG-3 138 60
5-GGAAGGAAGGCTGGAAGAGTG-3
Neurotensin 5-GCATGCTACTCCTGGCTTTC-3 131 60
5-CCAGAGGGACATGTGCTT-3
Osteopontin 5-CCAAGTAAGTCCAACGAAAGCC-3 273 58
5-GTACTGGATGTCAGGTCTGCG-3
Aldore
reductase 5-AGCAGCCAGGATATGACCAC-3 89 60
5-GGGTAATCCTTGTGGGAGGT-3
LTBP1 5-CTTCCGCTGCCTCTGTTATC-3 125 60
5-ACCCTTCCACGTTTTCACAG-3
GRO- 5-GAAAGCTTGCCTCAATCCTG-3 107 60
5-CSCCSGTGSGCTTCCTCCTC-3
IL-1RA 5-GCAGTCACCTAATCACTCTCC-3 228 60
5-CCAAGAACAGAGCATGAGGC-3
LTBR 5-CCATATGCGTCGGAGAACCAG-3 349 59
5-CAGGCGGGCAGTCAGAAAGTAG-3




IV 5-AGTCCCCCATCAACATCGTCAC-3 345 60
5-GCACCGCAATTTCGTCTTCAG-3
Trefoil
factor 1 5-GGTCGCCTTTGGAGCAGAGA-3 205 59
5-CGTCGAAACAGCAGCCCTTATT-3
CRBP1 5-TGTCCCGGCAGTCTCCAG-3 380 59
5-CCACGCCCCTCCTTCTCA-3
PLTP 5-GGCACCACCATCTCTGTCACTG-3 344 59
5-AATCCCGCATGGTTCGTCAC-3
TGF-1 5-GCGCCCATCTAGGTTATTTC-3 284 59
5-CCAGGCGTCAGCACCAGTAG-3
Collagen
IV-5 5-TCCAGCTCTGGAAGGACCTA-3 89 60
5-CCAGGATTTCCCTTCTCTCC-3
PLAB 5-GACCTATGATGACTTGTTAGCC-3 143 60
5-CAGGAATCGGGTGTCTCAGG-3
BMP2 5-AACACTGTGCGCAGCTTCC-3 101 60
5-CTCCGGGTTGTTTTCCCAC-3
Decorin 5-TCAATGGACTGAACCAGATGA-3 145 60
5-CCTTGAGGAATGCTGGTGAT-3
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galectin 2, LI-cadherin, and hepatocyte growth factor–
like protein transcripts were decreased with a concomi-
tant up-regulation of genes of the extracellular matrix
such as matrilin 3, collagen type IV, Cyr61, fibrillin-like
protein, and latent TGF- binding protein 1 (LTBP1).
Several up-regulated genes were related to immune func-
tions and inflammation, such as osteopontin, interleukin
1 receptor antagonist (IL-1RA), and the chemokines
MIP-3/CCL20, IL-8, and GRO-. In contrast, we ob-
served a down-regulation by NS5A of STAT6 and two
members of the tumor necrosis factor receptor (TNFR)
family: TNFR1A and LTBR. Finally, the regulation of a
large group of genes encoding for lipid-binding proteins
or enzymes involved in lipid homeostasis was observed.
Some genes reported to be differentially expressed in
HCV-infected liver tissue changed their expression ac-
cordingly in our analysis. This group included the TGF-
superfamily member PLAB, HLA-DQA1, and Rho-B,
which were up-regulated during acute HCV infection in
chimpanzees,19 and the CDK inhibitor Kip2, IL-8, and
epidermal growth factor receptor, which were up-regu-
lated in HCV cirrhotic liver tissue.20
To validate the microarray data, real-time RT-PCR
analysis was undertaken. Transcript levels were deter-
mined for neurotensin, LTBP1, bone morphogenic pro-
tein 2 (BMP2), collagen IV-5, IL-1RA, carbonic
anhydrase IV, and decorin in clones T1, T2, F1, and F11
(Fig. 2). Real-time RT-PCR and microarray data were
highly concordant for all of these randomly selected genes
(see Fig. 2). Transcript levels were also determined using
semiquantitative RT-PCR for osteopontin, aldose reduc-
tase, GRO-, trefoil factor 1, cellular retinol binding pro-
tein 1, and phospholipid transfer protein (PLTP) in
clones T1, T2, F1, and F11. In agreement with the mi-
croarray data, transcripts for osteopontin, aldose reduc-
tase, and GRO- were increased in F1 and F11 compared
with control clones, while transcripts for trefoil factor 1,
cellular retinol binding protein 1, and PLTP were de-
Fig. 1. NS5A expression in Huh7 cell clones. Total proteins from Huh7
clones stably expressing NS5A (F1 and F11) and from control clones (T1
and T2), were separated via SDS-PAGE, transferred to nitrocellulose
membranes, and probed with anti-NS5A and anti–-actin antibodies.
Table 2. Genes Up-Regulated in NS5A-Expressing Huh7








Epidermal growth factor receptor X00588 2.5
Aldose reductase X15414 2.3
Signal transduction/cell proliferation
Adrenal-specific protein pG2 X17544 8
Gravin U81607 4.5
CDK inhibitor p57/Kip2 U22398 3.5
SH3-domain binding protein 2 AB000462 3
Bone morphogenetic protein 2 M22489 3
Pim-2 oncogene U77735 2.5
Phosphodiesterase 3A, cGMP-inhibited U36798 2.5
Ephrin receptor EphA5 L36644 2.5
Thromboxane A2 receptor D38081 2.3
Chimerin 1 X51408 2.3
Mitogen-activated protein kinase 1/extracellular
signal–regulated kinase 2 Z11695 2.2
Homeobox protein Cdx1 U51095 2.2
Guanine nucleotide binding protein J03260 2.2
Activin A receptor, type II M93415 2.2
Dual-specificity protein kinase 4 Y09305 2.2
RhoB M12174 2.1
TGF-Beta superfamily protein PLAB/GDF-15/MIC-1 AB000584 2
Dual-specificity phosphatase 1 X68277 2
Immune response
Interleukin 8 M28130 5
Osteopontin U20758 5
GRO- X54489 2.2
Interleukin 1 receptor antagonist X53296 2.2
MIP-3/CCL20 U64197 2
ISG20 U88964 2
TNF alpha-induced protein 2 M92357 2
Major histocompatibility complex class II (HLA-
DQA1) M34996 2
Extracellular matrix
Matrilin 3 AJ001047 3.5
Cysteine-rich, angiogenic inducer 61 U62015 3
Fibrillin-like protein U03877 3
Latent TGF- binding protein 1 M34057 2.5
Type IV collagen 5 chain U04520 2.3
Cell adhesion and motility
-Tubulin X01703 4.5
Integrin-associated protein/CD47 Z25521 2.5
Vimentin Z19554 2.2
Miscellaneous
Reticulon 1 L10333 3
Mg81 L08240 3
Chloride channel 5 X81836 2.5
Cytochrome P450, subfamily I X02612 2.3
Glycogen phosphorylase B U47025 2.1
Nova1 U04840 2
NOTE. mRNA from control clones T1 and T2 and from NS5A-expressing clones
F1 and F11 were hybridized onto Affymetrix oligonucleotide arrays as indicated in
Patients and Methods. For each gene, the fold change was calculated with
Affymetrix software, and up-regulated genes were selected. The  indicates a fold
change calculation for which the smaller value is replaced by an estimate of the
minimum value for detectable transcripts. Genes up-regulated following transient
expression of NSSA are shown in bold.
HEPATOLOGY, Vol. 40, No. 3, 2004 GIRARD ET AL. 711
creased in NS5A-expressing clones (data not shown).
Modification by NS5A of the mRNA levels for MIP-3/
CCL20, IL-8, and STAT6 was previously confirmed via
PCR.8
Genes Dysregulated in HCC. The strongest effect of
NS5A observed was a 12-fold up-regulation of neuroten-
sin transcript. Neurotensin is transiently expressed in the
fetal liver, suppressed in the adult liver, and re-expressed
in certain liver cancers.21 We identified additional genes
up-regulated by NS5A that were previously reported to be
overexpressed in HCC, such as epidermal growth factor
receptor, aldose reductase, and osteopontin.22–24 Decorin
expression suppressed in HCC25 was down-regulated by
NS5A. Modulation of neurotensin, aldose reductase, os-
teopontin, and decorin by NS5A was validated via RT-
PCR analysis (see Fig. 2 and data not shown).
Intrahepatic metastasis of HCC is observed frequently.
Loss of cell– cell contact caused by increased cell motility
is a critical step in cancer metastasis. Many genes involved
in cell adhesion, motility, and cytoskeleton remodeling
were regulated by NS5A. This group included vimentin,
-tubulin, scaffold protein gravin, LI-cadherin, trefoil
factors 1 and 2, and RhoB. It has been reported that RhoB
is involved in intrahepatic metastasis of human HCC.26
Finally, we observed a 2.2-fold increase of mitogen-
activated protein kinase 1/extracellular signal–regulated
kinase 2 mRNA expression. Mitogen-activated protein
kinase/extracellular signal–regulated kinase activation
may play an important role in the progression of HCC.27
Table 3. Genes Down-Regulated in NS5A-Expressing Huh7






Cell adhesion and motility
Trefoil factor 2 (SP) X51698  8.6
Galectin 2 M87860  5.7
Hepatocyte growth factor-like protein/MSP U37055  3.3
Trefoil factor 1 (pS2) X52003 2.9
Urokinase-type plasminogen activator receptor U09937  2.6
LI-cadherin X83228 2.5
Carcinoma-associated antigen GA733-2 M93036 2.3
CD97 U76764  2.3
Lymphocyte antigen 6 complex, locus D (E48) X82693  2.2
Signal transduction/cell cycle
Transcription elongation factor S-II D50495  3.9
Frizzled-5 U43318 3
Growth factor receptor-bound protein 14 L76687 2.8
ELK3/net transcription factor Z36715  2.4
Phosphoinositide-3-kinase Y10055  2.4
Cyclin F Z36714  2.3
Mitogen-activated protein kinase kinase 3 D87116 2.2
Calpain 1 X04366 2.2
Decorin M14219 2
Immune response
Lymphotoxin  receptor L04270  7.6
Tumor necrosis factor receptor 1A M58286 7.3
Complement component 4-binding protein,  L11244 2.6
Complement component 4-binding protein,  M62486 2.6
Omega Light Chain, prot 14.1 M34515  2.4
STAT6 U16031  2
Calcium-binding proteins
Inositol 1,4,5-triphosphate receptor, type 3 U01062  2.8
Reticulocalbin 1 D42073 2.4
Grancalcin M81637 2.3
SERCA1 U96781  2.2
S100 calcium binding protein P X65614 2
Metabolism
Cellular retinol binding protein 2 U13831 9
Carbonic anhydrase IV L10955  6
Glutathione S-transferase 2 X65727 4.3
Nuclear receptor SHP L76571 3.1
Phospholipid transfer protein L26232  2.9
Hepatocyte nuclear factor 1 (TCF2) X58840  2.5
Fatty acid binding protein 1 M10050 2.5
Carboxylesterase 1 L07765 2.5
Lipoprotein-associated phospholipase A2 U24577 2.4
Histidase D16626  2.4
Nuclear orphan liver X receptor  U22662  2.3
Glutamine transaminase K X82224  2.3
Solute carrier family 7, member 6 D87432 2.3
Galactokinase 1 L76927  2.2
Arylacetamide deacetylase L32179 2.2
Hydroxyacyl-CoA dehydrogenase, type II (ERAB) U73514 2
Apolipoprotein E receptor 2 Z75190 2
Cellular retinol binding protein 1 M11433 2
Miscellaneous
Neuronal pentraxin II U29195 4.3
Giant larvae (Drosophila) homolog X87342  4
GTP-binding protein hsr1 X66436  3.4
Predicted osteoblast protein (GS3786) D87120 2.9
H2A histone family, member A M60752 2.4
Carboxypeptidase N2 J05158  2.3
Guanylate cyclase 2C M73489 2.3
Cold shock domain protein A M24069 2.2
Fibrinogen-like protein 1 D14446 2.2
Hypertension-associated SA D16350  2.1
Kininogen M11437 2.1
LIM homeobox protein 1 U14755  2
KIAA0140 D50930 2
NOTE. mRNA from control clones T1 and T2 and from NS5A expressing clones
F1 and F11 were hybridized onto Affymetrix oligonucleotide arrays as indicated in
Patients and Methods. For each gene, the fold change was calculated with
Affymetrix software, and down-regulated genes were selected. The  indicates
fold change calculation for which the smaller value is replaced by an estimate of
the minimum value for detectable transcripts. Genes down-regulated following
transient expression of NSSA are shown in bold.
Fig. 2. Effects of NS5A on Huh7 gene expression. Total RNA from T1,
T2, F1, and F11 Huh7 clones was reverse-transcribed, and real-time PCR
amplification was performed for neurotensin, LTBP1, BMP2, collagen
IV-5, IL-1RA, carbonic anhydrase IV, and decorin as described in
Patients and Methods. Transcript levels in F1 and F11 were normalized
using actin mRNA levels and compared with T1 and T2 controls. Data are
shown as mean  SEM of the independent microarray experiments.
Abbreviations: LTBP1, latent TGF- binding protein 1; BMP2, bone
morphogenic protein 2; IL-1RA, interleukin 1 receptor antagonist; PCR,
polymerase chain reaction.
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TGF- Superfamily Members and Modulators of
Fibrosis. TGF- is a potent modulator of liver fibrogen-
esis. In our microarray analysis, TGF-1 mRNA levels
remained unchanged between control and NS5A-express-
ing cells. Similar results were obtained via RT-PCR assay
(Fig. 3A).
Remarkably, expression of LTBP1, a component of the
latent TGF-1 complex, was increased by 2.5-fold.
LTBP1 is involved in the assembly, secretion, and target-
ing of TGF-1 to sites at which it is stored and/or acti-
vated.28 Positive staining for TGF- and LTBP was
observed in liver biopsies from HCV patients in areas
with inflammation and fibrosis.29 To determine if higher
levels of LTBP1 mRNA in NS5A-expressing cells corre-
lated with a modification of TGF-1 protein secretion,
TGF-1 expression was determined with enzyme-linked
immunosorbent assay in controls, T1, T2, and NS5A-
expressing clones F1 and F11. The pattern of TGF-1
protein expression was not significantly different in the
culture supernatants between T1, T2, F1, and F11 clones,
reaching 323  39 (mean  SEM) pg/mL, 327  20
(mean  SEM) pg/mL, 249  28 (mean  SEM) pg/
mL, and 392  121 (mean  SEM) pg/mL in T1, T2,
F1, and F11 respectively, at 48 hours (Fig. 3B).
Concomitant to the increase of LTBP1, we observed a
twofold decrease of the gene coding for decorin. Decorin
neutralizes TGF- bioactivity and reduces fibrosis. In ad-
dition, transcripts for 2 members of the TGF- superfam-
ily, BMP2 and PLAB, were up-regulated by three- and
twofold, respectively, in the NS5A-expressing clones
compared with controls. PLAB is up-regulated during
acute liver injury and liver regeneration.30 The HBV pX
protein enhances TGF-, BMP2, and activin transcrip-
tional activity, contributing to HBV-associated liver fi-
brosis.31 It must be noted that the receptor of activin A,
another member of the TGF- superfamily increased in
fibrotic liver, was also up-regulated by 2.2-fold in NS5A-
expressing cells.
We also observed an increase in type IV collagen. High
type IV collagen expression was reported in large fibrotic
areas and serum type IV collagen levels correlated with
fibrotic grades of HCV liver patients.32,33 Finally, we and
others reported previously that NS5A induces IL-8 ex-
pression.8,9 Elevated IL-8 expression correlated with liver
fibrosis in HCV patients.34
Regulation by NS5A of LTBP1, decorin, PLAB,
BMP2, collagen IV-5, and IL-8 was confirmed via RT-
PCR analysis (see Fig. 2 and data not shown).9
Thus, the increased levels of LTBP1, PLAB, BMP2,
activin A receptor, type IV collagen, and IL-8 on the one
hand and the decrease of decorin on the other may con-
tribute to hepatic fibrosis associated with HCV. In addi-
tion, NS5A may play critical roles in controlling TGF-
activity, by modulating LTBP1 and decorin gene expres-
sion.
Inflammation and Immune Response. Expression of
genes implicated in inflammatory process and immune
response was modulated by NS5A. TNF-related cyto-
kines are recognized as crucial effectors of the innate and
adaptive immune defenses, and targeting members of the
TNF/lymphotoxin superfamily and their receptors is a
strategy used by many viruses. Of great interest, therefore,
was the observation that expression of two members of the
TNF receptor family, TNFR1A and LTBR, were strongly
down-regulated (7.6- and 7.3-fold, respectively) in the
NS5A-expressing clones compared with controls. This
effect was subsequently confirmed via PCR analysis (Fig.
4A). We wished to determine the protein expression levels
for both genes. Although the sensitivity of Western blot-
ting was not sufficient to detect the TNFR1A protein in
Huh7 cells, the analysis of LTBR protein expression in-
dicated that LTBR protein levels were strongly reduced in
Fig. 3. Effect of NS5A on the TGF-1 gene expression and protein
secretion in Huh7 cells. (A) Total RNA from T1, T2, F1, and F11 Huh7
clones was reverse-transcribed and PCR amplification was performed for
TGF-1. (B) Secretion of TGF-1 protein in NS5A-expressing cells as
determined with enzyme-linked immunosorbent assay. T1, T2, F1, and
F11 Huh7 clones were cultured for 2 days in OPTIMEM I medium (GIBCO
BRL), and TGF-1–secreted protein was measured in the supernatants
every 24 hours.
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both NS5A-expressing clones F1 and F11 compared with
control cells T1 and T2 (Fig. 4B).
Our data, which are in agreement with those of oth-
ers,35,36 support a role for NS5A as a negative regulator in
TNF- signaling cascade. Interestingly, an up-regulation of
TNFR1A was observed in chimpanzee liver during acute
HCV infection, correlating with viral clearance.19 Therefore,
we could speculate that the down-regulation of TNFR1A
and LTBR by NS5A may confer to HCV the ability to
escape immune suppression leading to persistent infection.
IL-1 is one of the most important cytokines with
respect to the liver. IL-1RA counterbalances the biological
activity of IL-1 by a competitive binding to IL-1 recep-
tors. Increased levels of IL-1 and IL-1RA have been
found in the sera of patients with chronic liver diseases.
We observed a 2.2-fold increase in IL-1RA mRNA levels,
which was confirmed via real-time RT-PCR (see Fig. 2).
Other genes that are involved in inflammation and are
modulated by NS5A included osteopontin, hepatocyte
growth factor–like protein (which was implicated in he-
patic responses to inflammatory stimuli), calpain 1, and
lipoprotein-associated phospholipase A2. We also ob-
served a down-regulation of STAT6 by NS5A. STAT6 is
a mediator of IL-12 and IL-4 functions, and activation of
STAT6 may regulate liver inflammation injury.37 The
NS5A–up-regulated genes also included the proinflam-
matory chemokines IL-8 and GRO-.
Appropriate induction of a T helper 1 response is re-
quired for effective eradication of intracellular pathogens.
IL-12, which was first described for its ability to stimulate
IFN- production and enhance CD8 cytotoxicity, is a
dominant factor in T helper 1 phenotype development.
We observed an up-regulation of CD47 and a down-
regulation of mitogen-activated protein kinase kinase 3, 2
regulators of IL-12 production. CD47 ligation down-reg-
ulates IL-12 production,38 and mitogen-activated protein
kinase activating kinase 3 deficiency results in a severe
reduction of IL-12 production.39 In addition, T cells from
mice deficient in mitogen-activated protein kinase acti-
vating kinase 3 have a defect in IFN- production. It is
worth noting that the potential of dendritic cells gener-
ated from HCV-infected patients to stimulate allogeneic
CD4 T cells has been reported to be lower than that of
dendritic cells from healthy donors, potentially because of
low IL-12 expression.40
Complement also plays a protective role in the acute
host response against several viruses. The host uses a fam-
ily of proteins called regulators of complement activation to
prevent damage to host cells by activated complement;
these include the complement component 4–binding
protein, an important regulator of the classical pathway of
the complement system. Component 4–binding protein
acts as a cofactor in degradation of complement protein
C4b. Component 4–binding protein is mainly expressed
in the liver and is composed of the alpha and beta sub-
units. Its expression increases during inflammation, infec-
tion, or tissue damage. We observed a 2.6-fold decrease of
component 4–binding protein  and  in NS5A-ex-
pressing cells compared with controls.
Calcium Homeostasis and Cellular Signaling. It
was reported recently that NS5A alters calcium homeosta-
sis.41 Expression of several members of the family of pro-
teins known as EF-hand calcium-binding proteins such as
calpain 1, grancalcin, S100P, and the endoplasmic resi-
dent protein reticulocalbin 1 were reduced in NS5A-ex-
pressing cells. Other down-regulated genes included
inositol 1,4,5-triphosphate receptor type 3—an intracel-
lular channel that mediates the release of calcium from
intracellular stores—and sarco/endoplasmic reticulum
calcium adenosine triphosphatase 1, the latter of which
pumps calcium from the cytosol to the endoplasmic re-
ticulum and therefore plays a major role in the control of
calcium signaling.
Lipid Metabolism. Remarkably, microarray analysis
revealed a dysregulation upon NS5A expression of numer-
ous genes involved in lipid transport and metabolism. Sev-
eral lines of evidence suggest that the infection cycle of HCV
might involve lipoproteins and apolipoproteins. HCV asso-
ciates with low-density lipoprotein, including those contain-
Fig. 4. Effect of NS5A on gene and protein expression of the TNFR
family members LTBR and TNFR1A. (A) Total RNA from T1, T2, F1, and
F11 Huh7 clones was reverse-transcribed and PCR amplification was
performed for LTBR and TNFR1A. Lane 0 represents the negative control,
which was the product of RT-PCR where RNA was omitted. (B) Total
proteins extracted from T1, T2, F1, and F11 Huh7 clones were separated
via SDS-PAGE, transferred to nitrocellulose membranes, and probed with
anti-LTBR and anti–-actin antibodies. Abbreviations: LTBR, lymphotoxin
beta receptor; TNFR1A, tumor necrosis factor receptor 1A.
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ing apolipoproteins E and B. Recent studies have indicated
that lipoprotein-associated HCV particles may infect cells
via the low-density lipoprotein receptor.42 Furthermore,
binding of lipo-viro particles to the cell relies on apolipopro-
teins and their receptors, and this binding is efficiently inhib-
ited by normal low-density lipoprotein or very low-density
lipoprotein or antibodies to apolipoprotein B and apoli-
poprotein E.43 Remarkably, carriage of an apolipoprotein
E-4 allele may be protective against liver damage caused by
HCV.44 HCV infection is also often associated with the oc-
currence of liver steatosis. Interestingly, NS5A colocalizes
with the HCV core protein on lipid droplets and interacts
with apolipoprotein A1.45
Genes down-regulated by NS5A included PLTP
(which mediates phospholipid transfer, high-density li-
poprotein conversion, and reverse cholesterol transport),
fatty acid binding protein 1, lipoprotein-associated phos-
pholipase A2, the nuclear liver X receptor , arylacet-
Fig. 5. NS5A expression in Huh7 cells following transient transfections. (A) Amino acid sequence alignments of NS5A sequences. Full-length NS5A
sequences were cloned from 2 responders (R1 and R2) and 2 nonresponders (NR1 and NR2) to IFN- treatment. Amino acid residues are indicated
by the standard single-letter codes; dashes indicate the identical amino acid residues, with the consensus 1b sequence shown at the top. The position
of the interferon-sensitivity determining region (ISDR) is depicted in black. (B) Huh7 cells were transfected with NR1, NR2, R1, and R2
NS5A-expressing plasmids or with the empty vector. After 48 hours, total proteins were separated via SDS-PAGE, transferred to nitrocellulose
membranes, and probed with anti-NS5A and anti–-actin antibodies.
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amide deacetylase, and apolipoprotein E receptor 2.
Lipoprotein-associated phospholipase A2 is secreted by
liver cells and is associated with low- and high-density
lipoprotein. Liver X receptor , PLTP, and arylacetamide
deacetylase have all been associated with the production
and assembly of very low-density lipoprotein. ApoE re-
ceptor 2 belongs to the low-density lipoprotein receptor
family and functions in the uptake of apolipoprotein
E–containing lipoproteins.
These findings support an important role for NS5A in
modulating lipid homeostasis in hepatic cells that may
affect the viral life cycle and/or contribute to the develop-
ment of liver steatosis.
Comparison of 4 NS5A Sequences Isolated From
Responders and Nonresponders to IFN- Therapy.
To discriminate between early and late events or poten-
tially clonal effects, transient transfection assays were per-
formed in Huh7 cells with the plasmid-expressing NR1
NS5A mutant. NS5A protein expression was determined
48 hours posttransfection via Western blot analysis (Fig.
5B, lane 2). Microarray analysis was performed for two
independent experiments. Out of the 103 genes described
above, 34 genes were also identified as up- or down-reg-
ulated following transient expression of NS5A (P  .05)
as shown in bold in Tables 2 and 3. These genes included
IL-8, IL-1RA, fibrillin-like protein, and vimentin, which
were up-regulated, and galectin 2, trefoil factor 2, hepa-
tocyte growth factor–like protein, inositol 1,4,5-triphos-
phate receptor, type 3, calpain 1, and PLTP, which were
down-regulated upon NS5A expression. It is interesting
to note that both TNFR1A and LTBR were also down-
regulated following transient expression of NS5A. The
genes identified in the clones but not verified with the
transient expression system may be modulated by NS5A
by less than fourfold at 48 hours and therefore are not
selected because of the transfection efficiency of 50%–
60%, or they may be targets whose expression is modu-
lated by NS5A at a later time. A clonal effect resulting in
the selection of these genes cannot be excluded.
We subsequently compared the effects of NS5A mu-
tants isolated from responders and nonresponders to
IFN- therapy. In addition to the NR1 sequence, 3 full-
length NS5A sequences were obtained from 1 nonre-
sponder (NR2) and two responders (R1 and R2) (see Fig.
5A). NR1, NR2, R1, and R2 were transiently expressed in
Huh7 cells (see Fig. 5B). Total mRNA was prepared from
the Huh7 cells expressing transiently each of the 4 NS5A
sequences or the empty vector, and transcript levels were
determined using microarray analysis. Again, 2 indepen-
dent experiments were performed. Out of the 34 genes
Fig. 6. Activation of NF-B by NS5A. Huh7 cells were cotransfected
with NF-B–controlled luciferase plasmid along with NR1 NS5A expres-
sion plasmid or empty vector used as a control. Lysates from transfected
cells were prepared for luciferase activity.
Fig. 7. Adenovirus-mediated IB transfer reverts NS5A-dependent
gene up-regulation. F1 and F11 Huh7 clones were infected with adeno-
virus bearing IB or GFP, respectively. After 18 hours, total proteins and
RNA were extracted. (A) Total proteins were separated via SDS-PAGE,
transferred to nitrocellulose membranes, and probed with anti-IB and
anti--actin antibodies. (B) Total RNA was reverse-transcribed and real-
time PCR amplification was performed for aldose reductase, GRO-,
LTBP1, neurotensin, BMP2, and actin as described in Patients and
Methods. Transcript levels in F1-IB and F11-IB were normalized
using actin mRNA levels and compared with transcript levels in F1-GFP
and F11-GFP, respectively. Data are shown as mean  SEM of at least
3 independent experiments. Abbreviations: IB, inhibitor B; GFP,
green fluorescence protein; LTBP1, latent TGF- binding protein 1; BMP2,
bone morphogenic protein 2.
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regulated upon both stable and transient expression of
NR1 NS5A, 33 were also identified as up- or down-reg-
ulated by the 3 other NS5A mutants (NR2, R1, and R2).
Lipoprotein-associated phospholipase A2 transcript was
found to be down-regulated specifically by NS5A NR1
and NR2 proteins. However, this latter observation was
not confirmed in RT-PCR experiments (data not shown).
Therefore, no difference was detected among the NS5A
sequences derived from responders to IFN- therapy and
the NS5A sequences derived from nonresponders.
Computational Promoter and NF-B Binding Site
Analysis. We wished to predict putative transcription fac-
tors mediating NS5A effects on gene expression. A compu-
tational transcript mapping approach was used to locate
promoter sequences from the 43 up-regulated genes (see Ta-
ble 2). The promoter sequences of the 43 up-regulated genes
were submitted for analysis to MATCH, a pattern matching
program for searching putative transcription factor binding
sites in DNA sequences.16,17 Thirty-nine of the 43 gene pro-
moter regions contained 1 or more binding sites for nuclear
factor B (NF-B) (Supplementary Table 1), the large ma-
jority of them containing multiple NF-B binding sites. The
results included 6 genes known to be target genes of NF-B:
IL-8, GRO-, vimentin, IL-1RA, MIP-3/CCl20 and
epidermal growth factor receptor (http://people.bu.edu/
gilmore/nf-kb/target/).
We subsequently used the Gibbs sampling method18 to
derive overrepresented motifs in the upstream regions of
these 43 coinduced genes. To determine if this set of genes
may be coregulated by NF-B, motif lengths from 14–25 bp
were sampled from the 43 defined promoter regions to
search for conserved alignments. Seven returned motifs fit
the significant cut-off values (Wilcoxon P  .05), and all 43
genes were returned from the Gibbs sampler with a sequence
relating to the specified consensus sequence for all 7 motifs
(Supplementary Table 2). Therefore, computational analysis
of the 43 coinduced genes predicts that NF-B mediates
NS5A effects on gene expression.
NF-B Mediates NS5A Effects. To measure the
transcriptional activation of NF-B in NS5A-expressing
cells, Huh-7 cells were transfected with an empty vector
or NR1 NS5A expression plasmid, and induction of
NF-B was measured via cotransfection of a luciferase
gene driven by the E-selectin promoter. The E-selectin
promoter contains three functional NF-B sites, yields
robust induction, and is specific for NF-B.46 Expression
of NS5A leads to activation of NF-B as measured by
the reporter readout (Fig. 6). Significant increase in
NF-B activity was also observed in NS5A-expressing
clones F1 and F11 compared with control clones T1
and T2 (P  .012) (data not shown). This is in agree-
ment with a recent report suggesting an activation of
NF-B by NS5A.47 Activation of NF-B in the liver of
patients with chronic hepatitis C was also reported.48
NF-B is an important mediator of the inflammatory
response; however, its role in liver inflammation and
fibrosis remains controversial.
To confirm that NF-B mediates NS5A-dependent
gene regulation, we inhibited NF-B activity by infecting
NS5A expressing Huh7 clones F1 and F11, with adeno-
viruses AdIB or AdGFP expressing full-length IB
cDNA and GFP, respectively. The cells were tested for
IB expression via Western blotting (Fig. 7A). As shown
in Fig. 7B, adenovirus-mediated overexpression of IB
was effective at inhibiting the up-regulation of genes in-
duced by NS5A for aldose reductase, GRO-, LTBP1,
neurotensin, and BMP2, all randomly selected.
In conclusion, we identified 103 genes modified by
NS5A in the hepatocytic Huh-7 cells, many of which may
participate in the pathogenesis of HCV infection. To this
regard, the impact of NS5A protein mutations has yet to
be elucidated. In addition, activation of NF-B may play
an important role in HCV pathogenesis and development
of HCV-related liver diseases.
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